BioSyent Inc. (CVE:RX – Get Free Report) Director Seyed Ahmad Ashrafi sold 2,320 shares of the company’s stock in a transaction dated Friday, September 20th. The shares were sold at an average price of C$10.95, for a total transaction of C$25,404.00.
BioSyent Stock Performance
Shares of CVE:RX opened at C$11.00 on Wednesday. The company has a market cap of C$127.49 million, a price-to-earnings ratio of 18.33 and a beta of 0.93. The company has a 50-day moving average price of C$10.37 and a 200-day moving average price of C$9.52. The company has a current ratio of 6.13, a quick ratio of 6.91 and a debt-to-equity ratio of 3.19. BioSyent Inc. has a 12 month low of C$7.66 and a 12 month high of C$11.45.
BioSyent (CVE:RX – Get Free Report) last released its quarterly earnings results on Monday, August 26th. The company reported C$0.13 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of C$0.13. BioSyent had a net margin of 21.14% and a return on equity of 20.88%. The company had revenue of C$8.95 million during the quarter, compared to the consensus estimate of C$8.80 million. As a group, equities analysts anticipate that BioSyent Inc. will post 0.6785935 EPS for the current year.
BioSyent Company Profile
BioSyent Inc, together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia.
Read More
- Five stocks we like better than BioSyent
- How to Use Stock Screeners to Find Stocks
- Biohaven Stock Soars on Drug Trial Results: Time to Jump In?
- Comparing and Trading High PE Ratio Stocks
- Is AMD a Legitimate Threat to NVIDIA? What Investors Should Watch
- P/E Ratio Calculation: How to Assess Stocks
- Novo Nordisk’s Setback Won’t Last: A Game-Changing Drug Emerges
Receive News & Ratings for BioSyent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioSyent and related companies with MarketBeat.com's FREE daily email newsletter.